CN109311861B - 用于制备二苯基甲烷衍生物的方法 - Google Patents

用于制备二苯基甲烷衍生物的方法 Download PDF

Info

Publication number
CN109311861B
CN109311861B CN201780036968.1A CN201780036968A CN109311861B CN 109311861 B CN109311861 B CN 109311861B CN 201780036968 A CN201780036968 A CN 201780036968A CN 109311861 B CN109311861 B CN 109311861B
Authority
CN
China
Prior art keywords
compound
formula
alkyl
reaction
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780036968.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN109311861A (zh
Inventor
尹羲均
朴世换
尹址诚
崔珣奎
徐希静
朴恩婷
孔渶圭
宋光燮
金旼姝
朴劭屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Daewoong Pharmaceutical Co Ltd
Original Assignee
Green Cross Corp Japan
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109311861(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp Japan, Daewoong Pharmaceutical Co Ltd filed Critical Green Cross Corp Japan
Priority to CN202110860586.9A priority Critical patent/CN113651803B/zh
Publication of CN109311861A publication Critical patent/CN109311861A/zh
Application granted granted Critical
Publication of CN109311861B publication Critical patent/CN109311861B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780036968.1A 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法 Active CN109311861B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110860586.9A CN113651803B (zh) 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17
KR10-2016-0075910 2016-06-17
PCT/KR2017/006271 WO2017217792A1 (ko) 2016-06-17 2017-06-15 다이페닐메탄 유도체의 제조방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110860586.9A Division CN113651803B (zh) 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法

Publications (2)

Publication Number Publication Date
CN109311861A CN109311861A (zh) 2019-02-05
CN109311861B true CN109311861B (zh) 2021-08-24

Family

ID=60664449

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780036968.1A Active CN109311861B (zh) 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法
CN202110860586.9A Active CN113651803B (zh) 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110860586.9A Active CN113651803B (zh) 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法

Country Status (29)

Country Link
US (2) US10640496B2 (https=)
EP (2) EP3473621B1 (https=)
JP (4) JP6763978B2 (https=)
KR (2) KR102233229B1 (https=)
CN (2) CN109311861B (https=)
AU (1) AU2017285813B2 (https=)
CA (2) CA3026756C (https=)
CL (1) CL2018003645A1 (https=)
CO (1) CO2018014018A2 (https=)
DK (2) DK3473621T3 (https=)
DO (1) DOP2018000287A (https=)
EC (1) ECSP19000185A (https=)
ES (2) ES2898336T3 (https=)
HR (1) HRP20211670T8 (https=)
HU (1) HUE056428T2 (https=)
MA (2) MA44545B2 (https=)
MX (2) MX385640B (https=)
MY (1) MY203941A (https=)
NZ (1) NZ749398A (https=)
PE (2) PE20190467A1 (https=)
PH (1) PH12018550206A1 (https=)
PL (2) PL3663292T3 (https=)
PT (2) PT3473621T (https=)
RS (1) RS62550B1 (https=)
SA (2) SA521422474B1 (https=)
SG (2) SG11201811154QA (https=)
SI (1) SI3663292T1 (https=)
TN (1) TN2018000437A1 (https=)
WO (1) WO2017217792A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
WO2020036382A1 (ko) * 2018-08-13 2020-02-20 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체의 제조
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
CN115087649B (zh) 2020-02-27 2024-07-05 株式会社大熊制药 用于合成sglt抑制剂的中间体和使用该中间体制备sglt抑制剂的方法
WO2022051980A1 (zh) * 2020-09-10 2022-03-17 广东莱佛士制药技术有限公司 用于制备sglt抑制剂中间体的合成方法
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
CN113200860B (zh) * 2021-04-29 2024-07-30 爱斯特（成都）生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
KR20230046784A (ko) * 2021-09-30 2023-04-06 주식회사 대웅제약 이나보글리플로진을 포함하는 약학 조성물
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR20230110001A (ko) 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044190A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
KR20240044194A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
EP4595957A1 (en) 2022-09-29 2025-08-06 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition comprising enavogliflozin for preventing or treating cardiovascular aging diseases
WO2024076177A1 (ko) 2022-10-05 2024-04-11 주식회사 대웅제약 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물
KR20240099055A (ko) 2022-12-21 2024-06-28 주식회사 대웅테라퓨틱스 이나보글리플로진을 포함하는 점안제 형태의 약학 조성물
KR20240107660A (ko) 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물
KR102853437B1 (ko) * 2024-11-13 2025-09-04 대웅바이오(주) 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837948B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837941B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041898A1 (en) * 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN103596564A (zh) * 2011-06-01 2014-02-19 株式会社绿十字 作为sglt2抑制剂的新的二苯基甲烷衍生物
WO2015124877A1 (fr) * 2014-02-21 2015-08-27 Les Laboratoires Servier Dérivés de 5-benzylisoquinoléine pour le traitement de maladies cardiovasculaires
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
ES2531660T3 (es) * 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
PT2183263E (pt) 2007-07-26 2012-01-11 Lexicon Pharmaceuticals Inc Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio
TW201018695A (en) 2008-07-30 2010-05-16 Ferrer Int 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041898A1 (en) * 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN103596564A (zh) * 2011-06-01 2014-02-19 株式会社绿十字 作为sglt2抑制剂的新的二苯基甲烷衍生物
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
WO2015124877A1 (fr) * 2014-02-21 2015-08-27 Les Laboratoires Servier Dérivés de 5-benzylisoquinoléine pour le traitement de maladies cardiovasculaires

Also Published As

Publication number Publication date
SI3663292T1 (sl) 2022-01-31
CA3081033A1 (en) 2017-12-21
MA50774B1 (fr) 2022-02-28
SG11201811154QA (en) 2019-01-30
CA3026756A1 (en) 2017-12-21
RU2019101056A3 (https=) 2020-07-17
KR102233229B1 (ko) 2021-03-29
PL3663292T3 (pl) 2022-01-17
MX2018015647A (es) 2019-04-11
KR102379584B1 (ko) 2022-03-29
PH12018550206A1 (en) 2019-09-30
CO2018014018A2 (es) 2019-03-08
RU2019101056A (ru) 2020-07-17
MX385640B (es) 2025-03-18
MX392177B (es) 2025-03-19
JP2021152054A (ja) 2021-09-30
PT3663292T (pt) 2021-11-08
US20190382390A1 (en) 2019-12-19
MA50774A1 (fr) 2021-03-31
RS62550B1 (sr) 2021-12-31
JP2020117528A (ja) 2020-08-06
PL3473621T3 (pl) 2022-01-10
MA44545B1 (fr) 2020-05-29
EP3473621A4 (en) 2020-03-11
CN113651803A (zh) 2021-11-16
SG10201911782RA (en) 2020-02-27
JP7352509B2 (ja) 2023-09-28
HRP20211670T1 (hr) 2022-02-18
HRP20211670T8 (hr) 2022-03-18
JP2019521985A (ja) 2019-08-08
TN2018000437A1 (en) 2020-06-15
DK3473621T3 (da) 2021-09-06
MA44545B2 (fr) 2020-11-30
PE20240590A1 (es) 2024-03-21
AU2017285813A1 (en) 2019-01-17
CA3026756C (en) 2021-03-02
SA521422474B1 (ar) 2023-11-02
US10640496B2 (en) 2020-05-05
ECSP19000185A (es) 2019-01-31
EP3663292B1 (en) 2021-09-01
RU2021129636A (ru) 2021-11-22
JP6763978B2 (ja) 2020-09-30
AU2017285813B2 (en) 2020-02-06
CA3081033C (en) 2022-04-12
MA44545A1 (fr) 2019-10-31
EP3473621A1 (en) 2019-04-24
CN109311861A (zh) 2019-02-05
MX2021008988A (es) 2022-05-05
HUE056428T2 (hu) 2022-02-28
MY203941A (en) 2024-07-25
US20190169174A1 (en) 2019-06-06
JP7773506B2 (ja) 2025-11-19
ES2891825T3 (es) 2022-01-31
KR20210036892A (ko) 2021-04-05
JP2023145481A (ja) 2023-10-11
JP7669206B2 (ja) 2025-04-28
DK3663292T3 (da) 2021-10-25
EP3473621B1 (en) 2021-08-04
EP3663292A1 (en) 2020-06-10
ES2898336T3 (es) 2022-03-07
WO2017217792A1 (ko) 2017-12-21
SA518400666B1 (ar) 2021-11-30
BR112018076243A2 (pt) 2019-03-26
CL2018003645A1 (es) 2019-03-22
NZ749398A (en) 2020-01-31
US10889574B2 (en) 2021-01-12
CN113651803B (zh) 2022-10-28
KR20170142904A (ko) 2017-12-28
PE20190467A1 (es) 2019-04-04
DOP2018000287A (es) 2019-03-31
PT3473621T (pt) 2021-10-04

Similar Documents

Publication Publication Date Title
CN109311861B (zh) 用于制备二苯基甲烷衍生物的方法
CN105001213B (zh) C-芳基糖苷衍生物、其药物组合物、制备方法及应用
US20260078109A1 (en) Method for preparing sglt inhibitor
KR101770302B1 (ko) 다이페닐메탄 유도체의 제조방법
HK40057423A (en) Method for producing diphenylmethane derivative
HK40057423B (en) Method for producing diphenylmethane derivative
RU2814846C1 (ru) Способ получения производного дифенилметана
HK40002293A (en) Method for producing diphenylmethane derivative
RU2797392C2 (ru) Способ получения производного дифенилметана
RU2774998C2 (ru) Способ получения производного дифенилметана
HK40002293B (zh) 用於制备二苯基甲烷衍生物的方法
BR112018076243B1 (pt) Método para produzir um composto derivado de difenil metano e forma cristalina do composto produzido pelo dito método

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002293

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20190205

Assignee: DAEWOONG PHARMACEUTICAL Co.,Ltd.

Assignor: GREEN CROSS Corp.

Contract record no.: X2022990000919

Denomination of invention: Method for preparing diphenylmethane derivatives

Granted publication date: 20210824

License type: Exclusive License

Record date: 20221108